23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced the …
Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy
On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their …
Triumvira Immunologics Announces First Patient Dosed in Phase II of TACTIC-2 Cell Therapy Trial for the Treatment of HER2+ Gastric and GEJ Cancers
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that …
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for …
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer’s 38th Annual Meeting
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative …
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new …
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to …
Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment …
WHAT IS TARGETED THERAPY OR IMMUNOTHERAPY FOR PAEDIATRIC CANCERS?
The author of this article is Dr. Ruchira Misra, Sr. Consultant (Paediatric Haemato-Oncology and Bone Marrow …
